Experience of using azacytidine and venetoclax combination in acute myeloblastic leukemia

Authors

  • L.V. Mikhalska Center for Hematology, Chemotherapy, Hemoblastosis and Radiotherapy, Feofaniya Clinical Hospital of the Agency of State Affairs, Kyiv, Ukraine,
  • O.V. Kylivnyk Center for Hematology, Chemotherapy, Hemoblastosis and Radiotherapy, Feofaniya Clinical Hospital of the Agency of State Affairs, Kyiv, Ukraine,
  • O.O. Yamenko Center for Hematology, Chemotherapy, Hemoblastosis and Radiotherapy, Feofaniya Clinical Hospital of the Agency of State Affairs, Kyiv, Ukraine,

DOI:

https://doi.org/10.22141/2663-3272.3.1.2020.209823

Keywords:

acute myeloleukemia, azacytidine, venetoclax

Abstract

Acute myeloblastic leukemia (AML) commonly involve the elderly people, the average age at the moment of diagnosing is 68 years. According to the statistical data, only 2.4 % of people aged 60 and over who were not treated with stem cell transplantation experienced remission within 10 years after diagnosing, while most patients had an unfavorable prognosis of the disease. Unsatisfactory treatment results followed from severe comorbid conditions in such patients and a specific course of AML, namely a high rate of cytogenetic impairments causing the refractory course of the pathology. The therapy of lower intensity including hypomethylating agents (HMA) azacytidine and decitabine became the basic for elderly patients with AML who are poor candidates for intensive induction chemotherapy. The oral specific inhibitor of B-cell lymphoma/leukemia gene (BCL-2) venetoclax has been recently approved to be used in combination with HMA or low-dosage cytarabine in patients with AML who were not treated before or are not candidates for high-intensive chemotherapy. A described clinical case of using a treatment scheme of venetoclax + azacytidine demonstrates an opportunity to achieve remission in a 73-year patient with newly diagnosed AML with unfavorable prognosis.

References

Narayanan D., Weinberg O.K. How I investigate acute myeloid leukemia. Int. J. Lab. Hematol. 2020. 42. 3-15. DOI: 10.1111/ijlh.13135

Dianne Pulte D., Redaniel M., Jansen L., Brenner H., Jeffreys M. Recent Trends In Survival Of Adult Patients With Acute Leukemia: Overall Improvements, But Persistent And Partly Increasing Disparity In Survival Of Patients From Minority Groups. Haematologica. February 2013. 98. 222-229. doi:10.3324/haematol.2012.063602.

Bal B. et al. Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings. Leuk. Lymphoma. 2017 May. 58(5). 1022-1036. doi: 10.1080/10428194.2016.1228927.

National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: acute myeloid leukemia (AML) [Internet]. [cited 2019 Jun 30]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html. 2019

Vasu S., Kohlschmidt J., Mrózek K., Eisfeld A.-K., Nicolet D., Sterling L.J. et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018. 2. 1645-50.

Nagel G., Weber D., Fromm E., Erhardt S., Lubbert M., Fiedler W. et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann. Hematol. 2017. 96. 1993-2003.

Frohling S., Schlenk R.F., Kayser S. et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006 Nov 15. 108(10). 3280-3288.

Finn L., Dalovisio A., Foran J. Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. Ochsner J. Winter 2017. 17(4). 398-404.

NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3.2020. https://www.nccn.org/professionals/physician_gls/pdf/aml_blocks.pdf

Pleyer L. et al. Azacitidine for Front-Line Therapy of Patients With AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data With Registry Data From the Austrian Azacitidine Registry of the AGMT Study Group. Int. J. Mol. Sci. 2017 Feb 15. 18(2). 415. doi: 10.3390/ijms18020415.

Cashen A.F., Schiller G.J., O’Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 2010 Feb 1. 28(4). 556-561. doi: 10.1200/JCO.2009.23.9178.

Fenaux P., Mufti G.J., Hellstro¨m-Lindberg E. et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 2010 Feb 1. 28(4). 562-569. doi: 10.1200/JCO.2009.23.8329.

Kantarjian H.M., Thomas X.G., Dmoszynska A. et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 2012 Jul 20. 30(21). 2670-2677. doi: 10.1200/JCO.2011.38.9429.

Dombret H., Seymour J.F., Butrym A. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30 % blasts. Blood. 2015 Jul 16. 126(3). 291-299. doi: 10.1182/blood-2015-01-621664.

Pollyea D.A., Amaya M., Strati P. and Konopleva M.Y. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019. 3 (24). 4326-4335. https://doi.org/10.1182/bloodadvan­ces.2019000937]

Sudan N., Rossetti J.M., Shadduck R.K., Latsko J., Lech J.A., Kaplan R.B., Kennedy M., Gryn J.F., Faroun Y., Lister J. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006. 107(8). 1839.

DiNardo C.D., Pratz K., Pullarkat V. et al. Venetoclax combined with decitabine or azacitidine in treatmentnaive, elderly patients with acute myeloid leukemia. Blood. 2019. 133(1). 7-17.

Lachowiez C., DiNardo C.D., Konopleva M. Venetoclax in Acute Myeloid Leukemia — Current and Future Directions. Leuk. Lymphoma. 2020 Jun. 61(6). 1313-1322. doi: 10.1080/10428194.2020.1719098. Epub 2020 Feb 7.

Published

2020-02-01

Issue

Section

Practicing Physician